Herpes Simplex Virus Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: March 20, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.52 billion |
|
Revenue Forecast in 2031 |
US$ 2.68 billion |
|
CAGR |
5.6% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Drug Type, Route of Administration, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global herpes simplex virus treatment market was valued at US$ 1.52 billion in 2022 and is expected to register a revenue CAGR of 5.6% to reach US$ 2.68 billion by 2031.
Herpes Simplex Virus Treatment Market Fundamentals
Herpes simplex virus (HSV) is a highly contagious virus that causes cold sores, fever blisters, and genital herpes. There are two types of HSV: HSV-1 and HSV-2. HSV-1 usually causes cold sores on the mouth, lips, and face, while HSV-2 typically causes genital herpes. However, both types of the virus can cause sores in either location’s is spread through direct contact with an infected person, such as through kissing or sexual contact. Once infected, the virus can remain in their body for the rest of their life, although many people may never experience symptoms.
Several treatments are available for HSV infections, including antiviral medications, topical creams, pain relief medications, and home remedies. Antiviral medicines, such as acyclovir, valacyclovir, and famciclovir, help reduce the severity and duration of herpes outbreaks. Antiviral drugs work by blocking the virus’s ability to replicate. Over-the-counter or prescription creams containing docosanol, penciclovir, or acyclovir can help relieve symptoms of herpes outbreaks, such as itching, burning, and tingling. Over-the-counter pain relief medications, such as ibuprofen or acetaminophen, can help relieve pain associated with herpes outbreaks. Some people find relief from herpes symptoms by applying aloe vera gel, tea tree oil, or lemon balm to the affected area. However, there is limited scientific evidence to support the effectiveness of these remedies.
Currently, no commercially available vaccines prevent HSV infections. However, there are ongoing efforts to develop effective vaccines. Several vaccine candidates have been tested in clinical trials, but none have been approved for general use. For instance, in December 2022, BioNTech started a Phase 1 trial of BNT163 for HSV-1 and HSV-2. Some of the challenges in developing an effective vaccine include the ability of the virus to establish latency in the body, the variability of the virus strains, and the need for a vaccine that can elicit an immune response that can protect against both HSV-1 and HSV-2.
[6756]
Herpes Simplex Virus Treatment Market Dynamics
The global herpes simplex virus market is primarily driven by the high prevalence of the virus, the increase in awareness among people, and advancements in diagnostic and therapeutic technologies. HSV is one of the most common sexually transmitted infections worldwide, with millions of new cases yearly. According to the World Health Organization (WHO), an estimated 3.7 billion people under 50, or 67% of the population, are infected with HSV-1, and 417 million people aged 15-49 years are infected with HSV-2. This prevalence is thus driving the global market. There has been a significant increase in public awareness regarding the symptoms, transmission, and treatment options for HSV. This has increased the demand for diagnostic tests, antiviral medications, and vaccines. Developing sensitive and specific diagnostic tests has enabled early detection and accurate diagnosis of HSV infection.
The increasing healthcare expenditure in developing countries and the rising demand for quality healthcare services are expected to drive the growth of the HSV market. The growing focus of pharmaceutical companies on developing novel therapeutics and vaccines for HSV is expected to drive the market’s growth. Several drugs and vaccines are currently in clinical trials, offering a promising outlook for the market.
The global herpes simplex virus treatment market may face new hurdles due to high treatment costs and the increase in the prevalence of HSV encephalitis, which could impede market revenue growth. The adverse effects of drug consumption and a lack of awareness of herpes therapy constrain the market revenue growth.
Herpes Simplex Virus Treatment Market Ecosystem
The global herpes simplex virus treatment market has been analyzed from four perspectives: type, drug type, route of administration, and region.
Herpes Simplex Virus Treatment Market by Type
[75674]
Based on type, the global herpes simplex virus treatment market has been segmented into herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2).
The herpes simplex virus-1 (HSV-1) segment accounts for the largest revenue share in the global herpes simplex virus treatment market. This can be attributable to the rising prevalence of HSV-1 infection. For instance, the WHO estimates that 3.7 billion people worldwide over 50 are infected with HSV-1. Also, the market is driven by the rising risk of HSV-1 transmission, which can be contracted through oral-genital contact, contact with infected saliva, sores, or even sores on the skin. Also, the prevalence of HSV-1 encephalitis (HSE), a rare neurological condition brought on by the virus, is anticipated to increase the segment’s growth. The National Organization for Rare Diseases reports that HSE affects men and women equally and typically manifests in infancy or adulthood. Almost 2,000 cases of acute encephalitis and 10% of all cases reported in the United States are attributed to the disorder.
The herpes simplex virus-1 (HSV-2) segment is projected to grow at a steady revenue CAGR during the forecast period. The rise in cases of HSV-2 infection and the increased risk of HSV-2 reinfection in those with HSV-1 infection are both responsible for the expansion. Furthermore, the infection may be passed from the mother to the fetus, making prompt and appropriate treatment crucial. Businesses are developing new therapies. For instance, in October 2021, Cheng Kung University and Shanghai Public Health Clinical Centre collaborated with United BioPharma to examine the efficacy of UB-621 and phase II trials are anticipated to start in China and the United States.
Herpes Simplex Virus Treatment Market By Drug Type
Based on drug type, the global herpes simplex virus treatment market has been segmented into famciclovir, acyclovir, valacyclovir, and others.
The acyclovir segment is projected to observe the fastest revenue CAGR during the forecast period. This is because acyclovir is recognized as the best medication for treating herpes infections. According to statistics, 3,517,810 acyclovir prescriptions are anticipated to be written in the United States year 2020. The drug serves as a first-line antiviral agent and is offered in topical, oral, and intravenous formulations, which raises acceptance among the intended audience. Also, introducing over-the-counter medications for infection treatment further stimulates market expansion.
Herpes Simplex Virus Treatment Market by Route of Administration
Based on the route of administration, the global herpes simplex virus treatment market has been segmented into topical, injectable, and oral.
The oral segment accounts for the largest revenue share in the global HSV treatment market. The segment’s growth can be attributed to the efficiency and simplicity of the oral drug solutions. There are oral versions of acyclovir, valacyclovir, and famciclovir. Moreover, research has indicated that acyclovir reduces the average duration of cold sore pain by about 36% compared to a placebo when taken orally. Moreover, acyclovir has a 27% faster recovery period than other therapy formulations when taken orally. Also, oral formulations contribute to quick and quick action, which increases their adoption among the population.
The topical segment will observe the fastest revenue CAGR during the forecast period. The topical versions of acyclovir and penciclovir are available as creams. The amount of time that the discomfort lasts is decreased from around four days to three and a half days when penciclovir cream is used every two hours. While generally acknowledged, topical formulations are not meant to treat herpes simplex. They are typically administered to alleviate discomfort and suffering to hasten the healing of sores. Topical formulations are also user-friendly, making them practical and highly acceptable by a diverse spectrum of consumers, further driving up demand over the projection period.
Herpes Simplex Virus Treatment Market by Region
Based on region, the global herpes simplex virus treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share in the global herpes simplex virus treatment market. This can be attributed to the increase in the usage of branded herpes medications, the rise in healthcare costs, the growth in the introduction of generic medications, and supportive reimbursement policies. For instance, the CDC estimates that in the United States, 11.9% of individuals between the ages of 11 and 49 are infected. Rational Vaccines Inc. announced the launch of an observational clinical trial for their product RVx-001-PSS, which was expected to involve 200 patients with recurrent HSV-2 infection. The announcement was made in August 2022.
Asia Pacific is projected to observe a high revenue CAGR during the forecast period. Growing government measures to increase treatment uptake, expanding healthcare infrastructure, and regional expansion of major companies in Asian countries are contributing to the regional market’s growth. Also, the increasing herpes incidence in developing nations like China and India is anticipated to aid market revenue growth. As there are so many local businesses, the market is fragmented, contributing to the greater adoption rate of generics for herpes therapy in the region. The market is growing due to increased efforts to create a vaccine as a preventive approach to stop the spread of sickness.
Herpes Simplex Virus Treatment Market Competitive Landscape
The prominent players operating in the global herpes simplex virus treatment market are:
Herpes Simplex Virus Treatment Market Strategic Developments
The global herpes simplex virus treatment market is expected to grow at a revenue CAGR of 5.4% during the forecast period.
Viatris Inc., Teva Pharmaceuticals Industries Ltd., Sanofi SA, Novartis AG, and Emcure Pharmaceuticals Ltd. are among the key players in the global herpes simplex virus treatment market.
The acyclovir segment accounts for the largest revenue share in the global herpes simplex virus treatment market.
The increasing prevalence of herpes infection and pipeline vaccine candidates are driving the market revenue growth.
The global herpes simplex virus treatment market was valued at US$ 1.52 billion in 2022.
*Insights on financial performance are subject to the availability of information in the public domain